1. Maasumi K, Michael RL, Rapoport AM. CGRP and migraine: the role of blocking calcitonin gene-related peptide ligand and receptor in the management of migraine. Drugs. 2018;78(9):913–28.
2. Silberstein SD, Edvinsson L. Is CGRP a marker for chronic migraine? Neurology. 2013;81(14):1184–5.
3. Teva Pharmaceuticals Inc. AJOVYTM (fremanezumab-vfrm) injection, for subcutaneous use: US prescribing information. 2018.
http://www.fda.gov/
. Accessed 18 Sep 2018.
4. Teva Pharmaceutical Industries Ltd. Teva announces US approval of AJOVY™ (fremanezumab-vfrm) injection, the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive treatment of migraine in adults [media release]. 14 Sep 2018.
http://www.tevapharm.com/
.
5. Teva Pharmaceutical Industries Ltd. European Medicines Agency (EMA) accepts fremanezumab Marketing Authorization Application [media release]. 2 Feb 2018.
http://www.tevapharm.com/
.